ArticleInfection and drug resistance2019
In vitro activity of cefoperazone and cefoperazone-sulbactam against carbapenem-resistant
Article in Infection and drug resistance, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Efficacy and safety of cefoperazone-sulbactam in empiric therapy for febrile neutropenia: A systemic review and meta-analysis.Medicine · 2020Pooled it
- Clinical implications of cefoperazone-sulbactam MIC values inJAC-antimicrobial resistance · 2026Article
- Efficacy of cefoperazone-sulbactam as a component of combination therapy for carbapenem-resistant Acinetobacter baumannii bloodstream infection in intensive care units: a multicenter retrospective propensity score-matched study.BMC infectious diseases · 2025Article
- Unravelling the Antibiotic Resistance: Molecular Insights and Combating Therapies.Applied biochemistry and biotechnology · 2025Review
- Effectiveness and Safety of High-Dose versus Standard-Dose Cefoperazone-Sulbactam in Severe Infections: A Multicenter Retrospective Study.Infection and drug resistance · 2025Article
- Assessing the therapeutic efficacy of Cefoperazone Sodium and Sulbactam Sodium in managing surgical site infections: a retrospective analysis.Scientific reports · 2024Article
- Comparing the Outcomes of Cefoperazone/Sulbactam-Based and Non-Cefoperazone/Sulbactam-Based Therapeutic Regimens in Patients with MultiresistantAntibiotics (Basel, Switzerland) · 2024Review
- Article
- Ceftolozane/tazobactam: Literature review of its activity on Taiwanese isolates before its launch in Taiwan (2012-2021).Heliyon · 2024Review
- Prescribing Trends of Fixed-Dose Combination Antibiotics Not Recommended by the WHO (FNRs) for ICU Patients in Six Major Areas of China During a Seven-Year Period.Drug design, development and therapy · 2024Article
- The clinical features and risk factors of coagulopathy associated with cefoperazone/sulbactam: a nomogram prediction model.Frontiers in pharmacology · 2024Article
- Emergence and Evolution of OXA-23-Producing ST46Antibiotics (Basel, Switzerland) · 2023Article
- Correlation Between Cefoperazone/Sulbactam MIC Values and Clinical Outcomes of Escherichia coli Bacteremia.Infectious diseases and therapy · 2022Article
- Optimal Dose of Cefoperazone-Sulbactam for Acute Bacterial Infection in Patients with Chronic Kidney Disease.Antibiotics (Basel, Switzerland) · 2022Article
- Clinical Outcomes and Adverse Effects in Septic Patients with Impaired Renal Function Who Received Different Dosages of Cefoperazone-Sulbactam.Antibiotics (Basel, Switzerland) · 2022Article
- Integrated endotoxin-adsorption and antibacterial properties of platelet-membrane-coated copper silicate hollow microspheres for wound healing.Journal of nanobiotechnology · 2021Article
- Characteristics of and risk factors for biliary pathogen infection in patients with acute pancreatitis.BMC microbiology · 2021Article
- Clinical Efficacy of Cefoperazone-Sulbactam versus Piperacillin-Tazobactam in the Treatment of Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia.Infection and drug resistance · 2021Article
- Sulbactam Enhances in vitro Activity of β-Lactam Antibiotics AgainstInfection and drug resistance · 2021Article
- Compositional and drug-resistance profiling of pathogens in patients with severe acute pancreatitis: a retrospective study.BMC gastroenterology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to investigate the in vitro activity of cefoperazone-sulbactam against carbapenem-resistant MATERIALS AND
methodsIn total, 21 isolates of carbapenem-resistant
resultsFor carbapenem-resistant
conclusionThe in vitro antibacterial activity of cefoperazone against carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.